Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 5/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951287 | 0.88 | ADORA3 (0.57) | ADORA2AADORA3ADORA1SCD | |
| SCHEMBL19638133 | 0.87 | ADORA2A (0.53) | ADORA2AADORA3ADORA1 | |
| SCHEMBL19637941 | 0.87 | ADORA2A (0.62) | ADORA2AADORA3ADORA1 | |
| SCHEMBL19638124 | 0.84 | ADORA2A (0.53) | ADORA2AADORA3ADORA1 | |
| SCHEMBL19637977 | 0.83 | ADORA2A (0.48) | ADORA2AABL1ADORA3HDAC6ADORA1 | |
| SCHEMBL17951033 | 0.81 | ADORA3 (0.49) | ADORA2AADORA3 | |
| SCHEMBL18230507 | 0.80 | PCSK9 (0.48) | ADORA2AABL1ADORA3PCSK9ADORA1 | |
| SCHEMBL19638061 | 0.79 | ADORA3 (0.49) | ADORA2AADORA3ADORA1SCD | |
| SCHEMBL19637921 | 0.78 | ADORA3 (0.56) | ADORA2AADORA3 | |
| SCHEMBL19638140 | 0.78 | ADORA3 (0.63) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207445-B | Adenosine A3Modulators of receptors | 帕罗生物制药有限公司 | 2021-03-16 | — | — | CN | claimed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | claimed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | claimed |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-09-20 | — | — | US | claimed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | claimed |
| CN-107207445-B | Adenosine A3Modulators of receptors | 帕罗生物制药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-09-20 | — | — | US | disclosed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ABL1 4689/4885ADORA3 1/4885 |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ABL1 4689/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.